Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TETRACHEL vs ACTICLATE CAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.
Infections caused by susceptible strains of Rickettsiae,Mycoplasma pneumoniae infections,Psittacosis (ornithosis),Chlamydia trachomatis infections (e.g., uncomplicated urethral, endocervical, rectal),Brucellosis (in conjunction with streptomycin),Chancroid,Granuloma inguinale,Lymphogranuloma venereum,Relapsing fever,Bartonellosis,Plague,Tularemia,Acute intestinal amebiasis (adjunctive therapy),Severe acne,Propionibacterium acnes infections,Off-label: Helicobacter pylori eradication (as part of quadruple therapy)
Treatment of infections caused by susceptible bacteria, including respiratory tract infections, urinary tract infections, and acne vulgaris
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Tetracycline is primarily metabolized in the liver via glucuronidation and undergoes enterohepatic circulation. Minor metabolism may involve microsomal enzymes.
Primarily hepatic; metabolites include 4-epimino derivatives; not significantly metabolized via CYP450.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
65% (primarily albumin).
90-95% bound to serum proteins, primarily albumin
1.3 L/kg (extensive tissue penetration, including bone and teeth).
0.75 L/kg (50-70 L in adults); distributes well into tissues including bone, teeth, and synovial fluid
Oral: 77-96% (decreased by food, dairy, antacids).
Oral: 90-100% (capsule); food or dairy reduces absorption by up to 50%
Cr Cl >50 m L/min: no adjustment. Cr Cl 30-50 m L/min: 250 mg once daily. Cr Cl <30 m L/min: 125 mg once daily.
e GFR 30-59 m L/min: 350 mg once daily; e GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: 250 mg once daily. Child-Pugh C: 125 mg once daily.
Child-Pugh A: no adjustment; Child-Pugh B or C: 175 mg once daily.
Children ≥8 years: 5 mg/kg orally once daily (max 500 mg) for 28 days.
Not established for children <12 years; for ≥12 years, same as adult dosing.
Initiate at low end of dosing range; monitor renal function and adjust dose based on Cr Cl.
Initiate at 175 mg once daily; titrate cautiously based on renal function.
Tetracycline can cause fetal harm when administered to a pregnant woman. Use during tooth development (last half of pregnancy, infancy, and children up to 8 years) may cause permanent discoloration of teeth (yellow-gray-brown). It should not be used in this age group unless other drugs are not likely to be effective or are contraindicated.
Photosensitivity: severe sunburn can occur with sun exposure; discontinue if photosensitivity occurs. Tooth development: use during tooth development (last half of pregnancy, infancy, childhood to age 8) may cause permanent tooth discoloration. Bone growth: may retard bone growth in premature infants. Renal toxicity: may cause azotemia, hyperphosphatemia, and acidosis. Avoid in renal impairment.
Photosensitivity: exaggerated sunburn reaction; avoid direct sunlight and UV light.,Hepatotoxicity: may cause liver damage, especially in patients with renal impairment or receiving high doses.,Renal impairment: accumulation may occur; dosage adjustment required.,Superinfection: use of tetracycline may result in overgrowth of non-susceptible organisms, including fungi.,Pseudomembranous colitis: Clostridium difficile-associated diarrhea has been reported.,Intracranial hypertension: bulging fontanelles in infants and benign intracranial hypertension in adults.,Tissue irritation: avoid extravasation; thrombophlebitis risk with IV administration.
Photosensitivity, tooth discoloration, bone growth retardation, renal impairment, hepatotoxicity, increased intracranial pressure, superinfection, and use in pregnancy/lactation.
Hypersensitivity to tetracyclines or any component of the formulation.,Pregnancy (especially second and third trimesters) and lactation.,Children under 8 years of age (except for specific infections like anthrax or where no alternative exists).,Severe hepatic impairment.
Hypersensitivity to tetracyclines, pregnancy, breastfeeding, children under 8 years, renal impairment, and concurrent use with oral retinoids.
Avoid dairy products, calcium-fortified foods, and antacids containing calcium, magnesium, or aluminum, as they reduce absorption. Iron supplements, bismuth subsalicylate, and zinc also chelate tetracyclines. Take tetracycline 1 hour before or 2 hours after meals. Avoid alcohol (hepatotoxicity risk).
Avoid food and beverages for at least 1 hour before and after administration, as they can reduce the efficacy of activated charcoal. Do not mix with milk or ice cream, as they decrease binding capacity. Administer with water or a non-carbonated, non-alcoholic drink.
Tetracyclines, including Tetrachel, are classified as FDA Pregnancy Category D. They can cause fetal harm when administered to a pregnant woman. Use during the second and third trimesters (weeks 13 to 40) is associated with permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia in the child. Additionally, there is a risk of retarded skeletal growth and potentially reversible inhibition of bone growth. Use during the first trimester is generally discouraged unless no alternative therapy is available, as there may be a small risk of teratogenicity (e.g., neural tube defects, cardiovascular malformations) based on some observational studies, though evidence is conflicting.
First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known to cause permanent tooth discoloration (enamel hypoplasia) and reversible inhibition of bone growth; use contraindicated after 15 weeks gestation.
Tetracycline is excreted into human milk, with milk-to-plasma ratio (M/P) approximately 0.5-0.8. Low levels of tetracycline are found in breast milk; however, due to potential for serious adverse reactions (e.g., permanent tooth discoloration and bone growth inhibition) in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Alternative antibiotics with better safety profiles in lactation are preferred.
Tetracyclines are excreted in breast milk but absorption by the infant is limited due to chelation with milk calcium; M/P ratio for doxycycline is approximately 0.3-0.4. Theoretical risk of tooth staining and bone inhibition, but clinical significance is low with short-term use; caution with prolonged therapy.
Due to physiological changes in pregnancy (increased plasma volume, increased renal clearance), tetracycline may achieve lower serum concentrations. However, specific dosing adjustment guidelines for tetracycline in pregnancy are not established. The drug is generally avoided in pregnancy, particularly after the first trimester. If use is necessary in the first trimester, standard dosing based on non-pregnant adults is typically used, but careful monitoring for efficacy and toxicity is recommended. No dose adjustment is recommended for hepatic or renal impairment in pregnancy as the drug is contraindicated in such conditions.
No dosage adjustment is typically recommended for doxycycline in pregnancy due to minimal pharmacokinetic changes; however, use is generally avoided in the second and third trimesters. If indicated, standard dosing may be used in the first trimester with caution.
Tetracyclines are bacteriostatic antibiotics that inhibit protein synthesis. Avoid in children under 8 years and pregnant/breastfeeding women due to bone and tooth discoloration. Administer on an empty stomach (1 hour before or 2 hours after meals) with a full glass of water to prevent esophagitis. Do not take with dairy, antacids, or iron supplements as they chelate and reduce absorption. Photosensitivity risk: advise sun avoidance and sunscreen use.
ACTICLATE CAP is a high-dose activated charcoal formulation used for acute poisoning or overdose. Administer within 1 hour of ingestion for optimal efficacy. Do not use in patients with impaired consciousness unless the airway is protected. Monitor for vomiting and ensure rapid administration via nasogastric tube if necessary. Not effective for alcohols, metals, or caustics.
Take this medication on an empty stomach with a full glass of water.,Avoid dairy products, antacids, and iron supplements within 2 hours of taking this drug.,Use sunscreen and protective clothing to prevent severe sunburn.,Complete the full course of therapy even if you feel better.,Report any signs of allergic reaction, severe headache, or vision changes immediately.
Take ACTICLATE CAP only if directed by a healthcare professional after a poisoning or overdose.,This medication is not for regular use; it is a one-time emergency treatment.,Avoid taking this with food or drinks; take on an empty stomach for best absorption of toxins.,You may experience black stools or vomiting; this is normal.,Seek immediate medical attention if you have trouble swallowing, severe vomiting, or signs of bowel obstruction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TETRACHEL vs ACTICLATE CAP, answered by our medical review team.
TETRACHEL is a Tetracycline Antibiotic that works by Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.. ACTICLATE CAP is a Tetracycline Antibiotic that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TETRACHEL and ACTICLATE CAP depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TETRACHEL is: 500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.. The standard adult dose of ACTICLATE CAP is: 350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TETRACHEL and ACTICLATE CAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TETRACHEL is classified as Category C. Tetracyclines, including Tetrachel, are classified as FDA Pregnancy Category D. They can cause fetal harm when administered to a pregnant woman. Use during the second and third tri. ACTICLATE CAP is classified as Category C. First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.